Against this background, we undertook this study to further elucidate the complex interplay between impaired glucose regulation (e.g., fasting glucose), inflammation (e.g., SOD2) and hepatic damage in a well-characterized cohort of NAFLD patients. Here, SOD2 is linked to metabolic dysfunction-associated steatotic liver disease.